JP2016526920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526920A5 JP2016526920A5 JP2016533383A JP2016533383A JP2016526920A5 JP 2016526920 A5 JP2016526920 A5 JP 2016526920A5 JP 2016533383 A JP2016533383 A JP 2016533383A JP 2016533383 A JP2016533383 A JP 2016533383A JP 2016526920 A5 JP2016526920 A5 JP 2016526920A5
- Authority
- JP
- Japan
- Prior art keywords
- replication competent
- recombinant replication
- competent retrovirus
- retrovirus
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361862433P | 2013-08-05 | 2013-08-05 | |
| US61/862,433 | 2013-08-05 | ||
| PCT/US2014/049831 WO2015021077A1 (en) | 2013-08-05 | 2014-08-05 | Recombinant vector with optimized a-bulge |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016526920A JP2016526920A (ja) | 2016-09-08 |
| JP2016526920A5 true JP2016526920A5 (enExample) | 2017-09-14 |
Family
ID=52461883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533383A Pending JP2016526920A (ja) | 2013-08-05 | 2014-08-05 | 最適化a−バルジを有する組換えベクター |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3030659A4 (enExample) |
| JP (1) | JP2016526920A (enExample) |
| CN (1) | CN105579581A (enExample) |
| AU (1) | AU2014306093A1 (enExample) |
| CA (1) | CA2920049A1 (enExample) |
| WO (1) | WO2015021077A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| EP3856910B1 (en) | 2018-09-24 | 2024-11-20 | Merck Sharp & Dohme LLC | Expression vectors for eukaryotic expression systems |
| CN114127121B (zh) | 2019-08-12 | 2025-04-11 | 北京恩瑞尼生物科技股份有限公司 | 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物 |
| CN112569219B (zh) * | 2019-09-30 | 2023-05-02 | 中国科学院上海药物研究所 | 用于治疗动脉相关疾病的药物及其用途 |
| TW202128775A (zh) | 2019-10-16 | 2021-08-01 | 英商阿法克塔生命科學有限公司 | PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分 |
| KR20230010231A (ko) * | 2020-05-11 | 2023-01-18 | 아빈투스 바이오, 인코포레이티드 | 생체내 형질도입을 위한 벡터 및 방법 |
| GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
| EP4284834A1 (en) | 2021-01-29 | 2023-12-06 | Merck Sharp & Dohme LLC | Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof |
| WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
| EP4413038A1 (en) | 2021-10-07 | 2024-08-14 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
| TW202332694A (zh) | 2021-10-07 | 2023-08-16 | 英商阿凡克塔生命科學公司 | 血清半衰期延長之pd-l1結合多肽 |
| KR20250006965A (ko) | 2022-04-29 | 2025-01-13 | 퓨리노미아 바이오테크, 아이엔씨. | 호산구에 의해 유발되는 질환 및 장애의 치료를 위한 방법 및 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4937190A (en) * | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
| US20050260568A1 (en) * | 2004-04-30 | 2005-11-24 | Min Gao | Hepatitis C virus assays |
| US8829173B2 (en) * | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| WO2010036986A2 (en) * | 2008-09-26 | 2010-04-01 | Tocagen Inc. | Recombinant vectors |
| US20110020814A1 (en) * | 2009-06-05 | 2011-01-27 | Ipierian, Inc. | Methods and compositions for selection of stem cells |
| SG176890A1 (en) * | 2009-06-17 | 2012-01-30 | Tocagen Inc | Producer cells for replication competent retroviral vectors |
-
2014
- 2014-08-05 EP EP14835030.9A patent/EP3030659A4/en not_active Withdrawn
- 2014-08-05 WO PCT/US2014/049831 patent/WO2015021077A1/en not_active Ceased
- 2014-08-05 AU AU2014306093A patent/AU2014306093A1/en not_active Abandoned
- 2014-08-05 JP JP2016533383A patent/JP2016526920A/ja active Pending
- 2014-08-05 CN CN201480053358.9A patent/CN105579581A/zh active Pending
- 2014-08-05 CA CA2920049A patent/CA2920049A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526920A5 (enExample) | ||
| EP2909324B1 (en) | Retroviral vector with mini-promoter cassette | |
| US11279949B2 (en) | Recombinant vectors comprising 2A peptide | |
| US11788101B2 (en) | Genomic insulator elements and uses thereof | |
| US10975374B2 (en) | Combination vectors and methods for treating cancer | |
| JP2012503986A5 (enExample) | ||
| US20170175137A1 (en) | Retroviral vector having immune-stimulating activity | |
| JP2015533510A5 (enExample) | ||
| JP2012503987A5 (enExample) | ||
| JP2024045608A (ja) | 制御性rnaを発現させるためのベクターシステム | |
| JP2019503653A5 (enExample) | ||
| EP3030659A1 (en) | Recombinant vector with optimized a-bulge | |
| JP2023503858A (ja) | 4-1bblアジュバント添加した組み換え改変ワクシニアウイルスアンカラ(mva)の医学的使用 | |
| Everson et al. | Retroviral vector interactions with hematopoietic cells | |
| Hoang-Le et al. | A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy | |
| JP7378152B2 (ja) | Ssea4に結合するキメラ抗原受容体及びその使用 | |
| Abaan et al. | Gene therapy in human breast cancer | |
| Weber et al. | Retroviral vectors | |
| US11970708B2 (en) | Gene therapy vector with minimizing recombination, recombinant retrovirus comprising the vector, and pharmaceutical composition for preventing or treating cancer comprising the recombinant retrovirus | |
| RU2697797C2 (ru) | Генетическая конструкция для индукции пролиферации периферических моноцитов in vitro | |
| EP4249596A1 (en) | New gene recombinant vaccinia virus and utilization thereof | |
| JP2024526878A (ja) | 調節されたウイルス送達システムおよびその使用 | |
| CN1162643A (zh) | 用于癌症治疗的分子嵌合体的制备方法及应用 | |
| HK40034205A (en) | Chimeric antigen receptors that bind to ssea4 and uses thereof | |
| WO2018073307A1 (en) | Mlv-based gene therapy with mutated integrase coupled to peptides |